The retrieved literature consistently evaluates the purported link between GLP-1 receptor agonists (such as semaglutide and liraglutide) and cancer risk. Multiple large clinical trial analyses, real-world database evaluations, systematic reviews, and target trial emulations (e.g., papers 1, 3, 4, 7, 9) find no causal link or increased incidence of thyroid or colorectal cancers associated with these medications. While a few pharmacovigilance reports or isolated case presentations exist (papers 3, 5, 7), authors explicitly note these are insufficient to establish causation and are outweighed by robust epidemiological and clinical trial data. Therefore, the claim that Ozempic causes cancer is refuted by the balance of high-quality evidence.